{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:08:47Z","timestamp":1793797727893,"version":"4.6.1"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Transplant-associated thrombotic microangiopathy (TA-TMA) is an increasingly recognized complication of allogeneic and autologous hematopoietic cellular therapy (HCT), associated with significant morbidity and mortality. Although the central drivers of the disease are thought to be endothelial damage and complement activation, no specific diagnostic biomarkers have been identified. TA-TMA is typically diagnosed using criteria comprised of non-specific clinical and laboratory features. Some patients will have a self-remitting course, but more than half develop multi-organ dysfunction or die, making prognostic biomarkers critical. Prevention of TA-TMA, an approach central to other HCT complications such as\u00a0graft-versus-host disease, is largely untested in part due to a lack of identified early high-risk biomarkers. We conducted a systematic review to summarize the diagnostic, early risk, and prognostic biomarkers of TA-TMA. We screened the titles and abstracts of 1524 citations. After screening out duplications, we read the abstracts of 979 papers and fully reviewed 132 full-text publications. Thirty-one publications fulfilled the inclusion criteria of more than five patients with TA-TMA and a reported measure of association with diagnosis, prognosis, or risk of later development of the disease. Fourteen studies (45%) were with adults, 12 (39%) were with children &amp;lt;18 years old, three included both children and adults, and two did not report age. There were 53 biomarker or biomarker signature entries, and a total of 27 unique biomarkers. Only four biomarkers reported sensitivity and specificity. The single biomarker with the most robust data was sC5b-9, which conferred diagnostic, prognostic, and risk implications. Studies of combinations of biomarkers were rare. No meta-analyses were performed because of significant heterogeneity between studies. The limitations of studies included small sample size, study designs with a high risk of bias (i.e., case\u2013control), the timing of sample collection, and the selection of controls. Furthermore, only two (6%) studies included a training and validation cohort. Cut-off points are needed to stratify groups, as most biomarkers do not have normal values, or normal values cannot be assumed in the HCT setting. In the future, multi-institutional, collaborative efforts are needed to perform rigorously designed, prospective studies with serially enrolled patients, with samples collected at the time of TA-TMA diagnosis, careful selection of controls, and validation of selected biomarkers and cut-off points in a separate cohort.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1064203","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:14:55Z","timestamp":1675358095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A systematic review of diagnostic, prognostic, and risk blood and urine biomarkers of transplant-associated thrombotic microangiopathy"],"prefix":"10.3389","volume":"13","author":[{"given":"Michelle L.","family":"Schoettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshil","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13371","article-title":"Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation","volume":"32","author":"Gavriilaki","year":"2018","journal-title":"Clin Transplant."},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-dose Carboplatin\/Etoposide\/Melphalan increases risk of thrombotic microangiopathy and organ injury after autologous stem cell transplantation in patients with neuroblastoma","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"Young","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1960816","article-title":"Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients","volume":"14","author":"Jodele","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: A practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr ."},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1097\/MOH.0000000000000687","article-title":"Emerging therapeutic and preventive approaches to transplant-associated thrombotic microangiopathy","volume":"28","author":"Schoettler","year":"2021","journal-title":"Curr Opin Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001315","article-title":"New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT","volume":"4","author":"Elfeky","year":"2020","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004933","article-title":"Acute GVHD BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults","volume":"6","author":"xVasu","year":"2022","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1473-0502(02)00020-4","article-title":"Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver","volume":"27","author":"Daly","year":"2002","journal-title":"Transfus Apher Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008058","article-title":"Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children","author":"Schoettler","year":"2022","journal-title":"Blood Adv"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2015","journal-title":"Blood."},{"key":"B13","article-title":"Gene abnormalities in transplant associated- thrombotic Microangiopathy: Comparison between recipient and donor \u2018 s DNA","volume":"122","author":"Millicent","year":"2021","journal-title":"Thromb Haemost."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001242","article-title":"Risk factors for transplant-associated thrombotic microangiopathy and mortality in a pediatric cohort","volume":"4","author":"Schoettler","year":"2020","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.10.002","article-title":"Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004218","article-title":"Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab","volume":"135","author":"Jodele","year":"2020","journal-title":"Blood."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.351","article-title":"Use of defibrotide to treat transplant-associated thrombotic microangiopathy: A retrospective study of the paediatric diseases and inborn errors working parties of the European society of blood and marrow transplantation","volume":"52","author":"Yeates","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation\u2013associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3324\/haematol.10699","article-title":"Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an international working group","volume":"92","author":"Ruutu","year":"2007","journal-title":"Haematologica."},{"key":"B22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbmt.2012.10.006","article-title":"Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with Tacrolimus\/Sirolimus-based graft-versus-Host disease prophylaxis","volume":"19","author":"Shayani","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4172\/2329-8820.1000152","article-title":"Transplant-associated thrombotic microangiopathy (TA-TMA) and consensus based diagnostic and therapeutic recommendations: Which TA-TMA patients to treat and when","volume":"2","author":"Uderzo","year":"2014","journal-title":"J Bone Marrow Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.145.145","article-title":"A biomarker-based grading system At onset of GvHD predicts NRM better than the modified glucksberg grading system","volume":"122","author":"Levine","year":"2013","journal-title":"Blood."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.07.004","article-title":"Biomarkers for diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation","volume":"21","author":"Akil","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.07.008","article-title":"Current definitions and clinical implications of biomarkers in graft-versus-Host disease","volume":"28","author":"Bidgoli","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1692721","article-title":"Linking complement activation, coagulation, and neutrophils in transplant-associated thrombotic microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb Haemost."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619892684","article-title":"Von willebrand factor as a predictor for transplant-associated thrombotic microangiopathy","volume":"26","author":"Xu","year":"2020","journal-title":"Clin Appl Thromb Hemost."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.695037","article-title":"Early elevation of complement factor ba is a predictive biomarker for transplant-associated thrombotic microangiopathy","volume":"12","author":"Okamura","year":"2021","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.01.009","article-title":"Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell transplantation","volume":"24","author":"Horv\u00e1th","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.3389\/fmed.2020.569291","article-title":"Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic microangiopathy after stem cell transplantation","volume":"7","author":"Mez\u00f6","year":"2020","journal-title":"Front Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28070","article-title":"The alternative complement pathway activation product ba as a marker for transplant-associated thrombotic microangiopathy","volume":"67","author":"Sartain","year":"2020","journal-title":"Pediatr Blood Cancer."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018020321","article-title":"Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD","volume":"2","author":"Wall","year":"2018","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann Hematol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2020.12.010","article-title":"Prognostic biomarkers for thrombotic microangiopathy after acute graft-versus-Host disease: A nested case-control study","volume":"27","author":"Li","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/bmt.2017.119","article-title":"Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD","volume":"52","author":"Zeisbrich","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703026","article-title":"Serum levels of soluble adhesion molecules in stem cell transplantation-related complications","volume":"27","author":"Matsuda","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199612)53:4<213::AID-AJH1>3.0.CO;2-0","article-title":"Plasma von willebrand factor antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura\/hemolytic uremic syndromes (TTP\/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM)","volume":"53","author":"Zeigler","year":"1996","journal-title":"Am J Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.09.005","article-title":"Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"19","author":"Arai","year":"2013","journal-title":"Biol Blood Marrow Transplant."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.03.002","article-title":"Circulating heme oxygenase-1 and complement activation in transplant-associated thrombotic microangiopathy","volume":"25","author":"Pan","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01390-y","article-title":"Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation","volume":"56","author":"Luft","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.619690","article-title":"Endothelial cells in emerging viral infections","volume":"8","author":"Fosse","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700185","article-title":"ST2 and endothelial injury as a link between GVHD and microangiopathy","volume":"376","author":"Rotz","year":"2017","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782870","article-title":"Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD","volume":"130","author":"Davies","year":"2017","journal-title":"Blood."},{"key":"B46","first-page":"59","article-title":"Impact of pre-transplant serum-IGF-1 on hematopoietic stem cell transplantation outcome in pediatric cancer patients","volume":"94","author":"Betzmann","year":"2021","journal-title":"Horm Res Paediatr"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.233478","article-title":"Endothelial injury, f-actin and vitamin-d binding protein after hematopoietic stem cell transplant and association with clinical outcomes","volume":"106","author":"Luebbering","year":"2021","journal-title":"Haematologica."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.010","article-title":"Impact of thrombotic microangiopathy on renal outcomes and survival after hematopoietic stem cell transplantation","volume":"24","author":"Postalcioglu","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4178-x","article-title":"Haptoglobin degradation product as a novel serum biomarker for hematopoietic stem cell transplant-associated thrombotic microangiopathy","volume":"34","author":"Schuh","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701928","article-title":"Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura","volume":"24","author":"Zeigler","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.019","article-title":"TA-TMA risk stratification: is there a window of opportunity to improve outcomes","author":"Jodele","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12996","article-title":"Thrombotic microangiopathy with concomitant GI aGVHD after allogeneic hematopoietic stem cell transplantation: Risk factors and outcome","volume":"100","author":"Zhang","year":"2018","journal-title":"Eur J Haematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/sj.bmt.1702648","article-title":"Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation","volume":"26","author":"Uderzo","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004530","article-title":"A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy","volume":"5","author":"Zhao","year":"2021","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and complement activation as predictors of survival in adult allogeneic hematopoietic cell transplantation","volume":"5","author":"Gavriilaki","year":"2021","journal-title":"HemaSphere."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.21792","article-title":"Fragmented red cell as a possible favorable prognostic marker of hematopoietic stem cell transplantation associated thrombotic microangiopathy","volume":"29","author":"Jekarl","year":"2015","journal-title":"J Clin Lab Anal"},{"key":"B57","article-title":"Endothelial damage and dysfunction in acute graft-versus-host disease","volume":"106","author":"Cordes","year":"2021","journal-title":"Haematologica."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02339","article-title":"Acute graft-vs.-Host disease-associated endothelial activation in vitro is prevented by defibrotide","volume":"10","author":"Martinez-Sanchez","year":"2019","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181a819a1","article-title":"Overadjustment bias and unnecessary adjustment in epidemiologic studies","volume":"20","author":"Schisterman","year":"2009","journal-title":"Epidemiology."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/ph15070845","article-title":"Complement system as a new target for hematopoietic stem cell transplantation-related thrombotic microangiopathy","volume":"15","author":"Ardissino","year":"2022","journal-title":"Pharmaceuticals."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2018.04.003","article-title":"Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies","volume":"55","author":"Jodele","year":"2018","journal-title":"Semin Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1064203\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:15:05Z","timestamp":1675358105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1064203\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":61,"alternative-id":["10.3389\/fimmu.2022.1064203"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1064203","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"article-number":"1064203"}}